BR112023001740A2 - Receptores de ligação ao antígeno, célula t transduzida, polinucleotídeo isolado, vetor, kit, método para tratar uma doença em um indivíduo e induzir a lise de uma célula-alvo e uso do receptor de ligação ao antígeno - Google Patents
Receptores de ligação ao antígeno, célula t transduzida, polinucleotídeo isolado, vetor, kit, método para tratar uma doença em um indivíduo e induzir a lise de uma célula-alvo e uso do receptor de ligação ao antígenoInfo
- Publication number
- BR112023001740A2 BR112023001740A2 BR112023001740A BR112023001740A BR112023001740A2 BR 112023001740 A2 BR112023001740 A2 BR 112023001740A2 BR 112023001740 A BR112023001740 A BR 112023001740A BR 112023001740 A BR112023001740 A BR 112023001740A BR 112023001740 A2 BR112023001740 A2 BR 112023001740A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- binding
- transduced
- cell
- kit
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 230000009089 cytolysis Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 230000027455 binding Effects 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4633—Antibodies or T cell engagers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
RECEPTORES DE LIGAÇÃO AO ANTÍGENO, CÉLULA T TRANSDUZIDA, POLINUCLEOTÍDEO ISOLADO, VETOR, KIT, MÉTODO PARA TRATAR UMA DOENÇA EM UM INDIVÍDUO E INDUZIR A LISE DE UMA CÉLULAALVO E USO DO RECEPTOR DE LIGAÇÃO AO ANTÍGENO. A presente invenção refere-se, em geral, a receptores de ligação ao antígeno com capacidade de ligação específica a um domínio Fc que compreende a mutação de aminoácido P329G de acordo com a numeração EU. A presente invenção também se refere a células T, transduzidas com um receptor de ligação ao antígeno que é recrutado por ligação/interação específica com o domínio Fc mutado de anticorpos terapêuticos. Além disso, a invenção se refere a um kit que compreende as células T transduzidas da invenção e/ou moléculas de ácido nucleico, vetores que codificam os receptores de ligação ao antígeno da presente invenção e anticorpos direcionados ao tumor que compreendem um domínio Fc mutado.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20189196 | 2020-08-03 | ||
EP21158659 | 2021-02-23 | ||
PCT/EP2021/071515 WO2022029051A1 (en) | 2020-08-03 | 2021-08-02 | Improved antigen binding receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023001740A2 true BR112023001740A2 (pt) | 2023-02-28 |
Family
ID=77411698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023001740A BR112023001740A2 (pt) | 2020-08-03 | 2021-08-02 | Receptores de ligação ao antígeno, célula t transduzida, polinucleotídeo isolado, vetor, kit, método para tratar uma doença em um indivíduo e induzir a lise de uma célula-alvo e uso do receptor de ligação ao antígeno |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230322950A1 (pt) |
EP (1) | EP4188964A1 (pt) |
JP (1) | JP2023536169A (pt) |
KR (1) | KR20230042292A (pt) |
CN (1) | CN116234831A (pt) |
AU (1) | AU2021322054A1 (pt) |
BR (1) | BR112023001740A2 (pt) |
CA (1) | CA3185687A1 (pt) |
CL (1) | CL2023000351A1 (pt) |
CO (1) | CO2023002334A2 (pt) |
CR (1) | CR20230045A (pt) |
IL (1) | IL298449A (pt) |
MX (1) | MX2023001148A (pt) |
PE (1) | PE20230998A1 (pt) |
TW (1) | TW202221021A (pt) |
WO (1) | WO2022029051A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116162168A (zh) * | 2021-11-25 | 2023-05-26 | 信达细胞制药(苏州)有限公司 | 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2378403A1 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
RS57895B1 (sr) | 2011-03-29 | 2019-01-31 | Roche Glycart Ag | Fc varijante antitela |
KR20190133723A (ko) * | 2017-03-27 | 2019-12-03 | 에프. 호프만-라 로슈 아게 | 개선된 항원 결합 수용체 |
-
2021
- 2021-08-02 IL IL298449A patent/IL298449A/en unknown
- 2021-08-02 AU AU2021322054A patent/AU2021322054A1/en active Pending
- 2021-08-02 PE PE2023000202A patent/PE20230998A1/es unknown
- 2021-08-02 TW TW110128324A patent/TW202221021A/zh unknown
- 2021-08-02 KR KR1020237003882A patent/KR20230042292A/ko unknown
- 2021-08-02 CN CN202180058637.4A patent/CN116234831A/zh active Pending
- 2021-08-02 CA CA3185687A patent/CA3185687A1/en active Pending
- 2021-08-02 CR CR20230045A patent/CR20230045A/es unknown
- 2021-08-02 BR BR112023001740A patent/BR112023001740A2/pt unknown
- 2021-08-02 WO PCT/EP2021/071515 patent/WO2022029051A1/en active Application Filing
- 2021-08-02 JP JP2023506514A patent/JP2023536169A/ja active Pending
- 2021-08-02 EP EP21758071.1A patent/EP4188964A1/en active Pending
- 2021-08-02 MX MX2023001148A patent/MX2023001148A/es unknown
-
2023
- 2023-01-31 US US18/162,508 patent/US20230322950A1/en active Pending
- 2023-02-03 CL CL2023000351A patent/CL2023000351A1/es unknown
- 2023-02-28 CO CONC2023/0002334A patent/CO2023002334A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202221021A (zh) | 2022-06-01 |
IL298449A (en) | 2023-01-01 |
KR20230042292A (ko) | 2023-03-28 |
US20230322950A1 (en) | 2023-10-12 |
CL2023000351A1 (es) | 2023-08-25 |
CR20230045A (es) | 2023-02-21 |
PE20230998A1 (es) | 2023-06-26 |
MX2023001148A (es) | 2023-02-22 |
WO2022029051A1 (en) | 2022-02-10 |
JP2023536169A (ja) | 2023-08-23 |
CO2023002334A2 (es) | 2023-05-19 |
AU2021322054A1 (en) | 2023-01-05 |
EP4188964A1 (en) | 2023-06-07 |
CN116234831A (zh) | 2023-06-06 |
CA3185687A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018001531A2 (pt) | construtos de anticorpo para cd70 e cd3 | |
BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
BR112018077375A2 (pt) | kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente | |
BR112017012910A2 (pt) | proteína de fusão que compreende três domínios de ligação a 5t4 e cd3 | |
CL2019002717A1 (es) | Receptores de unión a antígeno mejorados. | |
BR112013021460A2 (pt) | molécula de ligação ao antígeno variante, anticorpos isolado e que se liga ao antígeno carcinoembrionário humano, polinucleotídeo isolado, vetor, célula hospedeira, composição, métodos para induzir a lise celular de uma célula tumoral, de tratamento de um sujeito possuindo um câncer e para aumentar o tempo de sobrevida e uso | |
BR112014017165A2 (pt) | polipeptídeos de fator quimérico viii e seus usos | |
BR112018001638A8 (pt) | construtos de anticorpo biespecífico que se ligam à mesotelina e cd3 | |
BRPI0922350B8 (pt) | anticorpo humano que se liga ao fator de tecido humano e molécula biespecífica e seus usos, célula hospedeira eucariótica ou procariótica recombinante, composição farmacêutica, método para a produção de um anticorpo, composição de diagnóstico, método para detectar a presença de fator de tecido em uma amostra in vitro, kit para detectar a presença de fator de tecido em uma amostra eanticorpo antiidiotípico | |
BR112017020373A2 (pt) | anticorpos anti-ceacam6 e usos dos mesmos | |
BR112015020277A2 (pt) | moléculas de ligação para bcma e cd3 | |
BR112023001740A2 (pt) | Receptores de ligação ao antígeno, célula t transduzida, polinucleotídeo isolado, vetor, kit, método para tratar uma doença em um indivíduo e induzir a lise de uma célula-alvo e uso do receptor de ligação ao antígeno | |
BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
BRPI0507433B8 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
MX353382B (es) | Moleculas de union polipeptido de larga duracion. | |
Boldrup et al. | p63 Transcriptionally regulates BNC1, a Pol I and Pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation | |
Petrushanko et al. | Oxidation of Са2+-binding domain of NADPH oxidase 5 (NOX5): toward understanding the mechanism of inactivation of NOX5 by ROS | |
BR112012013915A8 (pt) | anticorpos anti-c4. 4a e usos dos mesmos | |
BR112021018734A2 (pt) | Receptores de células t e métodos de uso destes | |
CL2009000567A1 (es) | Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer. | |
BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
BR112022009290A2 (pt) | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 | |
BR112022012524A2 (pt) | Porção química de ligação que se liga especificamente a claudin18.2, polinucleotídeo, vetor, célula hospedeira, receptor de antígeno quimérico (car ), célula imune geneticamente modificada, composição farmacêutica, método de tratamento de um tumor ou câncer que expressa claudin18.2 | |
BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação |